TLPH

Talphera, Inc. (TLPH) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Talphera, Inc. is a specialty pharmaceutical company focused on developing innovative therapies for medically supervised settings. The company's primary resource allocation is dedicated to Niyad, a regional anticoagulant for the dialysis circuit, which has received Breakthrough Device Designation from the FDA. The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: The company recorded a non-cash gain of $1.223 million on the change in fair value of warrant liability, which significantly reduced the reported net loss.

Material Changes vs. Prior Period

• Operating Expenses: Increased by $1.005 million (34%) to $3.948 million.
  • R&D Expenses: Rose 41% to $1.650 million, driven by higher Niyad development costs and increased patient enrollment in the NEPHRO CRRT study.
  • SG&A Expenses: Rose 30% to $2.298 million, attributed to increased compensation (bonuses), consulting fees for market research, and board expenses.
• Other Income: Total other income increased to $1.392 million from $250 thousand, primarily due to a $1.223 million gain from the decrease in the fair value of warrant liabilities.
• Liquidity Position: Total cash and short-term investments increased to $21.1 million from $5.4 million in Q1 2025, bolstered by a private placement offering in March 2026.
• Capital Structure: The company issued 639,931 shares of common stock and pre-funded warrants in the third closing of its April 2025 Private Placement, raising approximately $4.1 million in gross proceeds.

Outlook, Risks, and Management Commentary

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash resources are not expected to fund operations for the next twelve months. Additional capital is required to fund planned operations, including the Niyad clinical trial.
• Financing Needs: The company plans to seek additional capital through public/private equity offerings, debt, or strategic collaborations. Failure to secure funding could force workforce reductions or delays in clinical trials.
• Nasdaq Compliance: On March 11, 2026, the company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to the common stock failing to maintain a minimum closing bid price of $1.00 for 30 consecutive business days. The company has 180 days to regain compliance.
• Discontinued Operations: The company sold assets related to DSUVIA to Alora Pharmaceuticals. Alora has discontinued sales efforts to non-DoD customers and requested withdrawal of the DSUVIA NDA, reducing expected future payments.
• Strategic Transactions: Following the announcement of Niyad clinical data, CorMedix, Inc. holds a Right of First Negotiation for 60 days to negotiate an acquisition of 100% of Talphera.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash exhaustion and the status of any new financing agreements post-filing.
• Nasdaq Status: Monitor the stock price to determine if the company will regain compliance with the $1.00 minimum bid price rule or if a reverse stock split is required.
• Clinical Trial Progress: Confirm enrollment rates and data readout timelines for the Niyad NEPHRO CRRT study, as this is the primary driver of R&D spend and future valuation.
• CorMedix Negotiations: Track the outcome of the 60-day exclusivity period with CorMedix regarding a potential acquisition.
• Supply Chain Risks: Assess the impact of tariffs and reliance on single-source suppliers in Asia for nafamostat active ingredients and finished goods.